Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:03:31 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:VKTX - VIKING THERAPEUTICS INC - http://www.vikingtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VKTX - Q0.363.21·64.150.863.42-1.25-1.93,059.4191,67824,62964.54  65.80  61.6499.41  8.2819:59:45Apr 1715 min RT 2¢

Recent Trades - Last 10 of 24629
Time ETExPriceChangeVolume
19:59:45Q63.60-1.072
19:59:28Q63.60-1.075
19:59:17Q63.40-1.275
19:48:37Q63.23-1.4410
19:48:20Q63.22-1.4540
19:48:19Q63.60-1.073
19:38:58Q63.22-1.451
19:37:44Q63.40-1.2712
19:35:54Q63.40-1.2710
19:31:43Q63.40-1.273

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-17 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
2024-03-26 07:03U:VKTXNews ReleaseViking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
2024-03-04 16:45U:VKTXNews ReleaseViking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-02-28 20:50U:VKTXNews ReleaseViking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
2024-02-27 16:19U:VKTXNews ReleaseViking Therapeutics Announces Proposed Public Offering of Common Stock
2024-02-27 07:03U:VKTXNews ReleaseViking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
2024-02-07 16:05U:VKTXNews ReleaseViking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
2024-01-31 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
2023-11-13 16:02U:VKTXNews ReleaseViking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting ‚ ® 2023
2023-11-02 16:03U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2023-10-25 16:05U:VKTXNews ReleaseViking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-23 07:05U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
2023-10-18 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023
2023-10-17 16:05U:VKTXNews ReleaseViking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
2023-10-10 16:05U:VKTXNews ReleaseViking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
2023-09-07 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2023-09-06 07:03U:VKTXNews ReleaseViking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
2023-07-26 16:05U:VKTXNews ReleaseViking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-19 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023
2023-05-16 07:00U:VKTXNews ReleaseViking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)